当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.

Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.

Abstract：

:Tumor lysis syndrome (TLS) has been described in over 40% of patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. We conducted a retrospective analysis to determine predictive factors for TLS. In 116 patients, the incidence of TLS was 46% (95% CI: 36-55%). In univariable analysis, female gender, greater number of prior therapies, Rai stages III-IV, adenopathy ≥ 10 cm, splenomegaly, del(11q), decreased albumin and increased absolute lymphocyte count, white blood cell count (WBC), β2-microglobulin, and lactate dehydrogenase were associated (P < 0.05) with TLS. In multivariable analysis, female gender, adenopathy ≥ 10 cm, elevated WBC, increased β2-microglobulin, and decreased albumin were associated with TLS (P < 0.05). With respect to patient outcomes, 49 and 44% of patients with and without TLS, respectively, responded to flavopiridol (P = 0.71). In a multivariable analysis, controlling for number of prior therapies, cytogenetics, Rai stage, age and gender, progression-free survival (PFS) was inferior in patients with TLS (P = 0.01). Female patients and patients with elevated β2-microglobulin, increased WBC, adenopathy ≥ 10 cm and decreased albumin were at highest risk and should be monitored for TLS with flavopiridol. TLS does not appear to be predictive of response or improved PFS in patients receiving flavopiridol.

journal_name

Leukemia

journal_title

Leukemia

authors

Blum KA,Ruppert AS,Woyach JA,Jones JA,Andritsos L,Flynn JM,Rovin B,Villalona-Calero M,Ji J,Phelps M,Johnson AJ,Grever MR,Byrd JC

doi

10.1038/leu.2011.109

subject

Has Abstract

pub_date

2011-09-01 00:00:00

pages

1444-51

issue

9

eissn

0887-6924

issn

1476-5551

pii

leu2011109

journal_volume

25

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Expression and regulation of IL-4 receptors on human monocytes and acute myeloblastic leukemic cells.

    abstract：:Evidence is presented that human monocytes and acute myeloblastic leukemic (AML) cells contain both high and low affinity binding sites for interleukin-4 (IL-4). On monocytes 183 +/- 132 high affinity binding sites per cell with a Kd of 60 +/- 29 pM and 1500 +/- 600 low affinity receptors with a Kd of 2.3 +/- 0.4 nM (...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Wagteveld AJ,van Zanten AK,Esselink MT,Halie MR,Vellenga E

    更新日期：1991-09-01 00:00:00

  • Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors.

    abstract：:Immunotherapy with T cell modified with gamma-retroviral or lentiviral (LV) vectors to express a chimeric antigen receptor (CAR) has shown remarkable efficacy in clinical trials. However, the potential for insertional mutagenesis and genotoxicity of viral vectors is a safety concern, and their cost and regulatory dema...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2016.180

    authors： Monjezi R,Miskey C,Gogishvili T,Schleef M,Schmeer M,Einsele H,Ivics Z,Hudecek M

    更新日期：2017-01-01 00:00:00

  • The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes.

    abstract：:The Wilms' tumor gene, WT1, is a tumor marker for leukemic blast cells. The WT1 expression levels were examined for 57 patients with myelodysplastic syndromes (MDS) (refractory anemia (RA), 35; RA with excess of blasts (RAEB) 14; RAEB in transformation (RAEB-t), six; and MDS with fibrosis, two) and 12 patients with ac...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401341

    authors： Tamaki H,Ogawa H,Ohyashiki K,Ohyashiki JH,Iwama H,Inoue K,Soma T,Oka Y,Tatekawa T,Oji Y,Tsuboi A,Kim EH,Kawakami M,Fuchigami K,Tomonaga M,Toyama K,Aozasa K,Kishimoto T,Sugiyama H

    更新日期：1999-03-01 00:00:00

  • Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells.

    abstract：:Glucocorticoid (GC) receptor (GR) phosphorylation and signature genes were studied in chronic lymphocytic leukemia (CLL) cells to help place GCs within modern treatment algorithms. In contrast to normal B and T cells, transcription of GC-regulated genes was not rhythmic and the synthetic GC dexamethasone (DEX) could n...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-019-0381-4

    authors： Shi Y,Wang G,Muhowski EM,McCaw L,Wang C,Bjarnason G,Woyach JA,Spaner DE

    更新日期：2019-07-01 00:00:00

  • Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia.

    abstract：:To assess the efficacy and toxicity of HAA regimen (homoharritonine 4 mg/m2/day, days 1-3; cytarabine 150 mg/m2/day, days 1-7; aclarubicin 12 mg/m2/day, days 1-7) as an induction therapy in the treatment of de novo acute myeloid leukemia (AML), 48 patients with newly diagnosed AML, aged 35 (14-57) years, were entered ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404287

    authors： Jin J,Jiang DZ,Mai WY,Meng HT,Qian WB,Tong HY,Huang J,Mao LP,Tong Y,Wang L,Chen ZM,Xu WL

    更新日期：2006-08-01 00:00:00

  • Potential involvement of the AML1-MTG8 fusion protein in the granulocytic maturation characteristic of the t(8;21) acute myelogenous leukemia revealed by microarray analysis.

    abstract：:The AML1 (RUNX1)-MTG8 (ETO) fusion transcription factor generated by the t(8;21) translocation is believed to deregulate the expression of genes that are crucial for normal differentiation and proliferation of hematopoietic progenitors, resulting in acute myelogenous leukemia. To elucidate the role of AML1-MTG8 in leu...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402465

    authors： Shimada H,Ichikawa H,Ohki M

    更新日期：2002-05-01 00:00:00

  • Expression of the CEA gene family members NCA-50/90 and NCA-160 (CD66) in childhood acute lymphoblastic leukemias (ALLs) and in cell lines of B-cell origin.

    abstract：:The carcinoembryonic antigen (CEA) and the classical non-specific cross-reacting antigens (NCAs) belong to the CEA gene family which is part of the immunoglobulin superfamily. In normal hematopoiesis, CEA gene family members (CGMs) have only been reported on cells of myeloid and monocytic origin. In the present study,...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Hanenberg H,Baumann M,Quentin I,Nagel G,Grosse-Wilde H,von Kleist S,Göbel U,Burdach S,Grunert F

    更新日期：1994-12-01 00:00:00

  • Microsatellite instability in childhood T cell acute lymphoblastic leukemia.

    abstract：:Acute lymphoblastic leukemia (ALL) is the most frequent cancer encountered in children. Little is known about the molecular pathology of childhood T cell ALL. Oncogenesis is a multistep process that involves alterations in proto-oncogenes and tumor suppressor genes. Recently, a mutator phenotype detectable by microsat...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400650

    authors： Baccichet A,Benachenhou N,Couture F,Leclerc JM,Sinnett D

    更新日期：1997-06-01 00:00:00

  • Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome.

    abstract：:Chronic lymphocytic leukemia (CLL) remains incurable with chemoimmunotherapy, and allogeneic hematopoietic stem cell transplantation (HSCT) offers the potential for cure. We assessed the outcomes of 108 CLL patients undergoing first allogeneic HSCTs, 76 with reduced-intensity (RIC) and 32 with myeloablative conditioni...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2012.228

    authors： Brown JR,Kim HT,Armand P,Cutler C,Fisher DC,Ho V,Koreth J,Ritz J,Wu C,Antin JH,Soiffer RJ,Gribben JG,Alyea EP

    更新日期：2013-02-01 00:00:00

  • Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial.

    abstract：:PTEN gene inactivation by mutation or deletion is common in pediatric T-cell acute lymphoblastic leukemia (T-ALL), but the impact on outcome is unclear, particularly in patients with NOTCH1/FBXW7 mutations. We screened samples from 145 patients treated on the MRC UKALL2003 trial for PTEN mutations using heteroduplex a...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2015.206

    authors： Jenkinson S,Kirkwood AA,Goulden N,Vora A,Linch DC,Gale RE

    更新日期：2016-01-01 00:00:00

  • IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951.

    abstract：:The added value of IKZF1 gene deletion (IKZF1(del)) as a stratifying criterion in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is still debated. We performed a comprehensive analysis of the impact of IKZF1(del) in a large cohort of children (n=1223) with BCR-ABL1-negative BCP-ALL treated in the EORTC-CLG tr...

    journal_title：Leukemia

    pub_type： 杂志文章,随机对照试验

    doi：10.1038/leu.2015.134

    authors： Clappier E,Grardel N,Bakkus M,Rapion J,De Moerloose B,Kastner P,Caye A,Vivent J,Costa V,Ferster A,Lutz P,Mazingue F,Millot F,Plantaz D,Plat G,Plouvier E,Poirée M,Sirvent N,Uyttebroeck A,Yakouben K,Girard S,Dastu

    更新日期：2015-11-01 00:00:00

  • Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma.

    abstract：:Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-a subtype of Hodgkin lymphoma (HL)-is characterized by a low content of tumor cells, the lymphocyte predominant (LP) cells. Transformation into diffuse large B-cell lymphoma (DLBCL) occurs in about 10% of patients. We performed whole-genome mutation analysis of t...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2015.328

    authors： Hartmann S,Schuhmacher B,Rausch T,Fuller L,Döring C,Weniger M,Lollies A,Weiser C,Thurner L,Rengstl B,Brunnberg U,Vornanen M,Pfreundschuh M,Benes V,Küppers R,Newrzela S,Hansmann ML

    更新日期：2016-04-01 00:00:00

  • BCR/ABL-mediated downregulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CCL19 and CCL21 in primary BCR/ABL-positive cells.

    abstract：:The mechanism underlying p210(BCR/ABL) oncoprotein-mediated transformation in chronic myelogenous leukemia (CML) is not fully understood. We hypothesized that p210(BCR/ABL) suppresses expression of genes which may explain at least some of the pathogenetic features of CML. A subtractive cDNA library was created between...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403626

    authors： Jongen-Lavrencic M,Salesse S,Delwel R,Verfaillie CM

    更新日期：2005-03-01 00:00:00

  • Effect of deoxycytidine on the metabolism and cytotoxicity of 5-aza-2'-deoxycytidine and arabinosyl 5-azacytosine in normal and leukemic human myeloid progenitor cells.

    abstract：:The effect of deoxycytidine (dCyd) on the inhibitory effects of two antileukemic nucleoside analogs, 5-aza-2'-deoxycytidine and ara-5-aza-Cyd, toward the clonogenic growth of normal human bone marrow progenitors (CFU-GM) and leukemic blast progenitors (L-CFU) was examined. Continuous exposure of cells to 10(-6)-10(-5)...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Bhalla K,Cole J,MacLaughlin W,Arlin Z,Baker M,Graham G,Grant S

    更新日期：1987-12-01 00:00:00

  • Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas.

    abstract：:Mantle cell lymphoma represent a clinicopathologically distinct entity of malignant non-Hodgkin's lymphoma (NHL) and are characterized by a specific chromosomal translocation t(11;14)(q13;q32) involving the cyclin D1 gene also designated as bcl-1/PRAD1 gene on chromosome 11 and the heavy chain immunoglobulin joining r...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401172

    authors： Pott C,Tiemann M,Linke B,Ott MM,von Hofen M,Bolz I,Hiddemann W,Parwaresch R,Kneba M

    更新日期：1998-10-01 00:00:00

  • Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.

    abstract：:Histone deacetylase (HDAC) inhibitors, which are approved for the treatment of cutaneous T-cell lymphoma and multiple myeloma, are undergoing evaluation in other lymphoid neoplasms. How they kill susceptible cells is incompletely understood. Here, we show that trichostatin A, romidepsin and panobinostat induce apoptos...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2016.357

    authors： Ding H,Peterson KL,Correia C,Koh B,Schneider PA,Nowakowski GS,Kaufmann SH

    更新日期：2017-07-01 00:00:00

  • Correction: Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients.

    abstract：:Following the publication of this article, the authors noted that Patrick M. Vanderboom was inadvertently omitted from the author list. The correct author list is as follows: Sanjay Kumar, David Murray, Surendra Dasari, Paolo Milani, David Barnidge, Benjamin Madden, Patrick M. Vanderboom, Taxiarchis Kourelis, Bonnie A...

    journal_title：Leukemia

    pub_type： 已发布勘误

    doi：10.1038/s41375-019-0405-0

    authors： Kumar S,Murray D,Dasari S,Milani P,Barnidge D,Madden B,Kourelis T,Arendt B,Merlini G,Ramirez-Alvarado M,Dispenzieri A

    更新日期：2019-04-01 00:00:00

  • The murine long-term multi-lineage renewal marrow stem cell is a cycling cell.

    abstract：:Prevailing wisdom holds that hematopoietic stem cells (HSCs) are predominantly quiescent. Although HSC cycle status has long been the subject of scrutiny, virtually all marrow stem cell research has been based on studies of highly purified HSCs. Here we explored the cell cycle status of marrow stem cells in un-separat...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.252

    authors： Goldberg LR,Dooner MS,Johnson KW,Papa EF,Pereira MG,Del Tatto M,Adler DM,Aliotta JM,Quesenberry PJ

    更新日期：2014-04-01 00:00:00

  • KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.

    abstract：:To characterise the genetics of splenic marginal zone lymphoma (SMZL), we performed whole exome sequencing of 16 cases and identified novel recurrent inactivating mutations in Kruppel-like factor 2 (KLF2), a gene whose deficiency was previously shown to cause splenic marginal zone hyperplasia in mice. KLF2 mutation wa...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2014.330

    authors： Clipson A,Wang M,de Leval L,Ashton-Key M,Wotherspoon A,Vassiliou G,Bolli N,Grove C,Moody S,Escudero-Ibarz L,Gundem G,Brugger K,Xue X,Mi E,Bench A,Scott M,Liu H,Follows G,Robles EF,Martinez-Climent JA,Oscier D,Wa

    更新日期：2015-05-01 00:00:00

  • Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes.

    abstract：:Specific myeloid-related and inositide-specific gene mutations can be linked to myelodysplastic syndromes (MDS) pathogenesis and therapy. Here, 44 higher-risk MDS patients were treated with azacitidine and lenalidomide and mutations analyses were performed at baseline and during the therapy. Results were then correlat...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-019-0416-x

    authors： Follo MY,Pellagatti A,Armstrong RN,Ratti S,Mongiorgi S,De Fanti S,Bochicchio MT,Russo D,Gobbi M,Miglino M,Parisi S,Martinelli G,Cavo M,Luiselli D,McCubrey JA,Suh PG,Manzoli L,Boultwood J,Finelli C,Cocco L

    更新日期：2019-09-01 00:00:00

  • Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.

    abstract：:Unlike the case with acute myeloid leukemia, there is limited information on the prognostic impact of isocitrate dehydrogenase (IDH) mutations in myelodysplastic syndromes (MDS). In the current study of 277 patients with MDS, IDH mutations were detected in 34 (12%) cases: 26 IDH2 (all R140Q) and 8 IDH1 (6 R132S and 2 ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2011.298

    authors： Patnaik MM,Hanson CA,Hodnefield JM,Lasho TL,Finke CM,Knudson RA,Ketterling RP,Pardanani A,Tefferi A

    更新日期：2012-01-01 00:00:00

  • Secondary chromosomal abnormalities in acute leukemias.

    abstract：:Secondary chromosomal aberrations reported in the literature were surveyed in acute myeloid or lymphoblastic leukemia (AML or ALL) with one of the following primary abnormalities: in AML, t(1;3), t(1;22), der(1;7), inv(3), t(3;5) +4, del(5q), t(6;9), -7, t(7;11), del(7q), +8, t(8;16), t(8;21), +9, t(9;11), del(9q), t(...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Johansson B,Mertens F,Mitelman F

    更新日期：1994-06-01 00:00:00

  • T cell receptor alpha mRNA transcription in T-lymphoblastic transformation of chronic myelocytic leukemia.

    abstract：:Analysis at the DNA and RNA level revealed a mature genetic marker profile in a case of T type blast crisis of chronic myelocytic leukemia. T cell receptor beta chain gene rearrangement as well as T cell receptor alpha mRNA transcription was demonstrated in blasts of the malignant clone. Corresponding findings were ob...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Valent P,Bartram CR,Radaszkiewicz T,Hinterberger W,Lechner K,Bettelheim P

    更新日期：1988-03-01 00:00:00

  • Hematopoietic differentiation of umbilical cord blood-derived very small embryonic/epiblast-like stem cells.

    abstract：:A population of CD133(+)Lin(-)CD45(-) very small embryonic/epiblast-like stem cells (VSELs) has been purified by multiparameter sorting from umbilical cord blood (UCB). To speed up isolation of these cells, we employed anti-CD133-conjugated paramagnetic beads followed by staining with Aldefluor to detect aldehyde dehy...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2011.73

    authors： Ratajczak J,Zuba-Surma E,Klich I,Liu R,Wysoczynski M,Greco N,Kucia M,Laughlin MJ,Ratajczak MZ

    更新日期：2011-08-01 00:00:00

  • BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Ev

    abstract：:The flow cytometric detection of minimal residual disease (MRD) in precursor-B-acute lymphoblastic leukemias (precursor-B-ALL) mainly relies on the identification of minor leukemic cell populations that can be discriminated from their normal counterparts on the basis of phenotypic aberrancies observed at diagnosis. Th...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402150

    authors： Lucio P,Gaipa G,van Lochem EG,van Wering ER,Porwit-MacDonald A,Faria T,Bjorklund E,Biondi A,van den Beemd MW,Baars E,Vidriales B,Parreira A,van Dongen JJ,San Miguel JF,Orfao A,BIOMED-I.

    更新日期：2001-08-01 00:00:00

  • CD44 isoforms distinguish between bone marrow plasma cells from normal individuals and patients with multiple myeloma at different stages of disease.

    abstract：:CD44 variant isoforms (CD44v) have been shown to be important factors in adverse prognosis in hematological malignancies. To investigate whether CD44 expression is associated with malignant transformation in multiple myeloma, RNA and protein expression of CD44 standard (CD44s) and CD44v4, v6, v9, v10 containing isofor...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401179

    authors： van Driel M,Günthert U,Stauder R,Joling P,Lokhorst HM,Bloem AC

    更新日期：1998-11-01 00:00:00

  • RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation.

    abstract：:Ikaros family zinc finger protein 1 and 3 (IKZF1 and IKZF3) are transcription factors that promote multiple myeloma (MM) proliferation. The immunomodulatory imide drug (IMiD) lenalidomide promotes myeloma cell death via Cereblon (CRBN)-dependent ubiquitylation and proteasome-dependent degradation of IKZF1 and IKZF3. A...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-019-0403-2

    authors： Zhou N,Gutierrez-Uzquiza A,Zheng XY,Chang R,Vogl DT,Garfall AL,Bernabei L,Saraf A,Florens L,Washburn MP,Illendula A,Bushweller JH,Busino L

    更新日期：2019-08-01 00:00:00

  • Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

    abstract：:The 2001 World Health Organization (WHO) treatise on the classification of hematopoietic tumors lists chronic myeloproliferative diseases (CMPDs) as a subdivision of myeloid neoplasms that includes the four classic myeloproliferative disorders (MPDs)-chronic myelogenous leukemia, polycythemia vera (PV), essential thro...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2404955

    authors： Tefferi A,Vardiman JW

    更新日期：2008-01-01 00:00:00

  • TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition.

    abstract：:T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological cancer characterized by skewed epigenetic patterns, raising the possibility of therapeutically targeting epigenetic factors in this disease. Here we report that among different cancer types, epigenetic factor TET1 is highly expressed in T-ALL a...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-020-0864-3

    authors： Bamezai S,Demir D,Pulikkottil AJ,Ciccarone F,Fischbein E,Sinha A,Borga C,Te Kronnie G,Meyer LH,Mohr F,Götze M,Caiafa P,Debatin KM,Döhner K,Döhner H,González-Menéndez I,Quintanilla-Fend L,Herold T,Jeremias I,Feuring-

    更新日期：2020-05-15 00:00:00

  • The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study.

    abstract：:In this open-label randomized clinical trial, HLA-identical sibling-matched hematopoietic stem cells (HSC) were transplanted (non-MSCs group, n=15) or cotransplanted with mesenchymal stem cells (MSCs) (MSCs group, n=10) in hematologic malignancy patients. The median number of MSCs infused was 3.4 x 10(5) kg(-1) (range...

    journal_title：Leukemia

    pub_type： 杂志文章,随机对照试验

    doi：10.1038/sj.leu.2405090

    authors： Ning H,Yang F,Jiang M,Hu L,Feng K,Zhang J,Yu Z,Li B,Xu C,Li Y,Wang J,Hu J,Lou X,Chen H

    更新日期：2008-03-01 00:00:00